Robles Sara, Hu Yanmei, Resto Tahyra, Dean Frank, Bullard James M
Chemistry Department, The University of Texas-RGV, 1201 W. University Drive, Edinburg, TX 78541. United States.
Curr Drug Discov Technol. 2017;14(3):156-168. doi: 10.2174/1570163814666170330100238.
Pseudomonas aeruginosa is an opportunistic pathogen problematic in causing nosocomial infections and is highly susceptible to development of resistance to multiple antibiotics. The gene encoding methionyl-tRNA synthetase (MetRS) from P. aeruginosa was cloned and the resulting protein characterized.
MetRS was kinetically evaluated and the KM for its three substrates, methionine, ATP and tRNAMet were determined to be 35, 515, and 29 μM, respectively. P. aeruginosaMetRS was used to screen two chemical compound libraries containing 1690 individual compounds.
A natural product compound (BM01C11) was identified that inhibited the aminoacylation function. The compound inhibited P. aeruginosa MetRS with an IC50 of 70 μM. The minimum inhibitory concentration (MIC) of BM01C11 was determined against nine clinically relevant bacterial strains, including efflux pump mutants and hypersensitive strains of P. aeruginosa and E. coli. The MIC against the hypersensitive strain of P. aeruginosa was 16 μg/ml. However, the compound was not effective against the wild-type and efflux pump mutant strains, indicating that efflux may not be responsible for the lack of activity against the wild-type strains. When tested in human cell cultures, the cytotoxicity concentration (CC50) was observed to be 30 μg/ml. The compound did not compete with methionine or ATP for binding MetRS, indicating that the mechanism of action of the compound likely occurs outside the active site of aminoacylation.
An inhibitor of P. aeruginosa MetRS, BM01C11, was identified as a flavonoid compound named isopomiferin. Isopomiferin inhibited the enzymatic activity of MetRS and displayed broad spectrum antibacterial activity. These studies indicate that isopomiferin may be amenable to development as a therapeutic for bacterial infections.
铜绿假单胞菌是一种机会致病菌,在引起医院感染方面存在问题,并且极易对多种抗生素产生耐药性。克隆了来自铜绿假单胞菌的甲硫氨酰 - tRNA合成酶(MetRS)基因,并对所得蛋白质进行了表征。
对MetRS进行了动力学评估,确定其三种底物甲硫氨酸、ATP和tRNA Met的KM分别为35、515和29μM。使用铜绿假单胞菌MetRS筛选了两个包含1690种单独化合物的化合物库。
鉴定出一种天然产物化合物(BM01C11),它抑制氨酰化功能。该化合物抑制铜绿假单胞菌MetRS的IC50为70μM。测定了BM01C11对九种临床相关细菌菌株的最低抑菌浓度(MIC),包括铜绿假单胞菌和大肠杆菌的外排泵突变体及超敏菌株。对铜绿假单胞菌超敏菌株的MIC为16μg/ml。然而,该化合物对野生型和外排泵突变体菌株无效,这表明外排可能不是其对野生型菌株缺乏活性的原因。在人细胞培养物中进行测试时,观察到细胞毒性浓度(CC50)为30μg/ml。该化合物不与甲硫氨酸或ATP竞争结合MetRS,表明该化合物的作用机制可能发生在氨酰化活性位点之外。
铜绿假单胞菌MetRS的抑制剂BM01C11被鉴定为一种名为异波米非林的类黄酮化合物。异波米非林抑制MetRS的酶活性并显示出广谱抗菌活性。这些研究表明异波米非林可能适合开发为治疗细菌感染的药物。